STROMILLO, MARIA LAURA
 Distribuzione geografica
Continente #
NA - Nord America 5.876
EU - Europa 4.637
AS - Asia 588
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 6
SA - Sud America 4
AF - Africa 3
Totale 11.120
Nazione #
US - Stati Uniti d'America 5.863
GB - Regno Unito 1.773
IE - Irlanda 805
CN - Cina 475
SE - Svezia 437
UA - Ucraina 429
IT - Italia 336
FR - Francia 326
DE - Germania 235
FI - Finlandia 118
ES - Italia 52
VN - Vietnam 41
BE - Belgio 29
NL - Olanda 16
TR - Turchia 16
MK - Macedonia 15
RU - Federazione Russa 14
CA - Canada 11
CZ - Repubblica Ceca 10
HK - Hong Kong 10
PH - Filippine 9
JP - Giappone 7
GR - Grecia 6
IL - Israele 6
AU - Australia 5
EU - Europa 5
IR - Iran 5
KR - Corea 5
HU - Ungheria 4
RS - Serbia 4
AL - Albania 3
AT - Austria 3
BG - Bulgaria 3
IN - India 3
MA - Marocco 3
PL - Polonia 3
DK - Danimarca 2
ID - Indonesia 2
KZ - Kazakistan 2
MD - Moldavia 2
PT - Portogallo 2
RO - Romania 2
SG - Singapore 2
SI - Slovenia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AR - Argentina 1
BR - Brasile 1
CH - Svizzera 1
CL - Cile 1
CR - Costa Rica 1
EE - Estonia 1
FK - Isole Falkland (Malvinas) 1
IM - Isola di Man 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
SA - Arabia Saudita 1
TH - Thailandia 1
Totale 11.120
Città #
Southend 1.639
Fairfield 959
Dublin 799
Ashburn 474
Chandler 469
Woodbridge 468
Menlo Park 439
Houston 377
Wilmington 377
Seattle 358
Jacksonville 354
Cambridge 331
Princeton 165
Ann Arbor 163
Siena 155
Nanjing 117
Beijing 106
Boardman 52
Málaga 51
San Mateo 51
Helsinki 47
San Diego 46
Dong Ket 40
Nanchang 37
New York 36
Lancaster 35
Shenyang 34
Düsseldorf 23
Norwalk 22
Tianjin 22
London 21
Florence 20
Changsha 19
Hebei 19
Brussels 18
Jiaxing 18
Kunming 18
Milan 17
Jinan 16
Dearborn 15
Los Angeles 14
Shanghai 13
Fremont 12
Izmir 12
San Francisco 10
Waanrode 10
Washington 10
Ningbo 9
Kilburn 8
Sacramento 8
Zhengzhou 8
Hangzhou 7
Toronto 7
Phoenix 6
Pisa 6
Renton 6
Rome 6
Skopje 6
Torino 6
Boston 5
Brno 5
Chicago 5
Lanzhou 5
Redwood City 5
Venezia 5
Amsterdam 4
Belgrade 4
Central 4
Falls Church 4
Frankfurt am Main 4
Fuzhou 4
Genoa 4
Hong Kong 4
Munich 4
Parma 4
Saint Petersburg 4
Tappahannock 4
Villacidro 4
Bonndorf 3
Brdo 3
Caserta 3
Changchun 3
Edinburgh 3
General Trias 3
Gyomro 3
Haikou 3
Hefei 3
Hounslow 3
Lappeenranta 3
Monte Porzio Catone 3
Mountain View 3
New Bedfont 3
Norwich 3
Seodaemun-gu 3
Sofia 3
Tokyo 3
Acton 2
Bologna 2
Cedar Knolls 2
Chelyabinsk 2
Totale 8.735
Nome #
Development and psychometric properties of a neuropsychological battery for mild cognitive impairment with small vessel disease: The VMCI-tuscany study 219
Appraisal of brain connectivity in radiologically isolated syndrome by modeling imaging measures 205
Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study 201
Mitochondrial dysfunction in hereditary spastic paraparesis with mutations in DDHD1/SPG28 187
Reliability, practice effects, and change indices for Rao's Brief Repeatable Battery. 185
null 182
Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis 178
Long-term assessment of no evidence of disease activity in relapsing-remitting MS 171
Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study 167
Gray matter atrophy cannot be fully explained by white matter damage in patients with MS 163
Cortical damage in brains of patients with adult-form of myotonic dystrophy type 1 and no or minimal MRI abnormalities 163
Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis 162
Relevance of brain lesion location to cognition in relapsing multiple sclerosis 160
Prognostic biomarkers of IFNb therapy in multiple sclerosis patients 157
Twelve-year monitoring of a patient with megalencephalic leukoencephalopathy with subcortical cysts 154
Structural and metabolic damage in brains of patients with SPG11-related spastic paraplegia as detected by quantitative MRI 154
Cortical lesions in radiologically isolated syndrome. 151
Clinical relevance of brain volume changes in patients with cerebrotendinous xanthomatosis 146
Clinical Course of Two Italian Siblings with Ataxia-Telangiectasia-Like Disorder. 146
Assessing response to interferon-β in a multicenter dataset of patients with MS 145
The Italian Neuroimaging Network Initiative (INNI): enabling the use of advanced MRI techniques in patients with MS 144
Scoring treatment response in patients with relapsing multiple sclerosis 144
Right-to-left shunt in CADASIL patients: prevalence and correlation with clinical and MRI findings 143
Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study 143
Peak width of skeletonized mean diffusivity (PSMD) as marker of widespread white matter tissue damage in multiple sclerosis 142
Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome 141
Automated identification of brain new lesions in multiple sclerosis using subtraction images 140
Pronounced structural and functional damage in early adult pediatric-onset multiple sclerosis with no or minimal clinical disability 140
Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis. 139
Brain metabolism changes after therapy with chenodeoxycholic acid in a case of cerebrotendinous xanthomatosis. 139
Increased QT variability in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. 138
Cardiac autonomic nervous system and risk of arrhythmias in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). 135
Cognitive reserve and cortical atrophy in multiple sclerosis: A longitudinal study 135
Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis 133
Peripheral neuropathy in vanishing white matter disease with a novel EIF2B5 mutation 131
MR evidence of structural and metabolic changes in brains of patients with Werner’s syndrome. 130
Impaired vasoreactivity in mildly disabled CADASIL patients 129
Refining response to treatment as defined by the Modified Rio Score 128
Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. 127
Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis 126
Deep gray matter volume loss drives disability worsening in multiple sclerosis 126
Rapidly progressive neurodegeneration in a case with the 7472insC mutation and the A7472C polymorphism in the mtDNA tRNA ser(UCN) gene. 126
Prominent brain axonal damage and functional reorganization in "pure" adrenomyeloneuropathy. 124
Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis 123
Diffuse structural and metabolic brain changes in Fabry disease 122
Subclinical motor impairment assessed with an engineered glove correlates with magnetic resonance imaging tissue damage in radiologically isolated syndrome 122
Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis 121
The Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Scale: A Screening Tool to Select Patients for NOTCH3 Gene Analysis. 121
Leukoencephalopathy as a rare complication of hepatitis C infection. 120
Association of MRI metrics and cognitive impairment in radiologically isolated syndromes 119
Cortical functional reorganisation and its relationship with brain structural damage in patients with benign multiple sclerosis 119
Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis. 118
Post-stroke depression: Research methodology of a large multicentre observational study (DESTRO) 118
null 117
Modelling the distribution of cortical lesions in multiple sclerosis 116
Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis 116
Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. 114
Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course 113
Diffuse metabolic changes in the brain of patients with familial amyloid polyneuropathy. A proton MRSI study. 112
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 112
null 108
Effects of Sapropterin on Endothelium-Dependent Vasodilation in Patients With CADASIL: A Randomized Controlled Trial 107
Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study 107
The dilemma of benign multiple sclerosis: Can we predict the risk of losing the “benign status”? A 12-year follow-up study 107
Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis. 104
Retinal nerve fibre layer thickness, lesional load and brain atrophy in patients with cerebral autosomal dominant arteriopathy with subcortical infarct and leucoencephalopathy (CADASIL) 103
Leukoencephalopathy, cerebral calcifications, and parenchimal cysts in two siblings. 103
null 102
APOE-{varepsilon}4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. 97
Imaging neuronal and axonal degeneration in multiple sclerosis. 93
Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis 91
A comparison of cognitive performances between multiple sclerosis patients with pediatric- versus adult onset disease 91
Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization 91
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 91
Structural MRI correlates of cognitive impairment in patients with multiple sclerosis: A Multicenter Study 86
null 84
Structural and Metabolic Brain Abnormalities in Preclinical Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarct and Leukoencephalopathy 82
Novel human pathological mutations. Gene symbol: NOTCH3. Disease: CADASIL, exon 2 mutation. 82
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 79
Peak width of skeletonized mean diffusivity (PSMD) and cognitive functions in relapsing-remitting multiple sclerosis 78
MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis 77
Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple Sclerosis 77
Short-Term Combination of Glatiramer Acetate with IV Steroid Treatment Preceding Treatment with GA Alone Is Associated with early Suppression of MRI-disease activity in Patients with Relapsing Remitting Multiple Sclerosis 77
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 72
Efficacy and safety of intravenous immunoglobulin treatment in refractory Behcet's Disease with different organ involvement: a case series 66
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 57
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 57
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 55
Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course 55
Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm 54
Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis 43
Vitamin D levels in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) 38
Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis 37
Operationalizing mild cognitive impairment criteria in small vessel disease: The VMCI-Tuscany Study 27
Hippocampal and deep gray matter nuclei atrophy is relevant for explaining cognitive impairment in MS: A multicenter study 25
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it? 23
Signs and symptoms of Covid‐19 in patients with multiple sclerosis 21
Effect of BDNF Val66Met polymorphism on hippocampal subfields in multiple sclerosis patients 18
Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative 16
Hippocampal atrophy in vascular MCI as biomarker of subclinical memory impairment 16
Totale 11.299
Categoria #
all - tutte 35.233
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.233


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019311 0 0 0 0 0 0 0 0 0 0 0 311
2019/20202.330 285 100 172 368 142 174 216 293 206 191 61 122
2020/20211.952 72 189 39 132 89 175 231 358 178 163 177 149
2021/20221.441 107 148 99 101 110 70 79 50 79 124 205 269
2022/20231.778 111 151 235 225 160 336 51 155 204 67 53 30
2023/20241.131 61 25 110 48 35 331 429 26 6 25 24 11
Totale 11.327